{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"67.5","value":"25.0"},{"groupId":"OG001","lowerLimit":"59.0","upperLimit":"100","value":"88.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"EFS will be calculated as time from the end of the three high-risk blocks of therapy to first event (relapse, second malignancy, remission death) or date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"VHR T-ALL patients (with end of consolidation \\[EOC\\] MRD \\>= 0.1%) who become MRD negative (MRD undetectable) after the three high-risk BFM blocks of therapy","id":"OG000","title":"VHR T-ALL MRD Undetectable"},{"description":"VHR T-ALL patients (with end of consolidation \\[EOC\\] MRD \\>= 0.1%) who continue to have detectable MRD after the three high-risk BFM blocks of therapy.","id":"OG001","title":"VHR T-ALL MRD Detectable"}],"paramType":"NUMBER","populationDescription":"VHR T-ALL patients who had EOC MRD \\>= 0.1%, completed the three high-risk blocks of therapy, and had MRD assessment done after the three high-risk blocks. MRD was not performed in T-LLy patients at end of the VHR blocks. MRD is not used in T-LLy to measure disease response. This outcome measure was pre-specified to only be assessed in the T-ALL patients.","reportingStatus":"POSTED","timeFrame":"3 years","title":"EFS for Very High Risk (VHR) T-ALL Patients Treated With High Risk (HR) Berlin-Frankfurt-Munster (BFM) Intensification Blocks Who Become Minimal Residual Disease (MRD) Negative and Those Who Remain MRD Positive at the End of HR Block 3","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}